TY - JOUR
KW - buprenorphine
KW - buprenorphine/naloxone
KW - naloxone
KW - narcotics
KW - opiate addiction
KW - Opiates
KW - opioid addiction
KW - Opioids
AU - R. A. Sansone
AU - L. A. Sansone
A1 - 
AB - While most clinicians will never prescribe buprenorphine or combined buprenorphine/naloxone, familiarity with the risks of these pharmacological approaches to the treatment of narcotic addiction remains relevant. Overall, medication-assisted treatment has clearly resulted in meaningful gains for a number of individuals who are addicted to narcotics (i.e., opiates and opioids). However, a certain level of risk is inherent with these approaches. For example, both buprenorphine and buprenorphine/naloxone may be diverted and misused (e.g., intravenously injected, intranasally administered), particularly buprenorphine. Likewise, when illicitly injected, both can cause infectious complications as well as result in death from overdose. The risk of death with buprenorphine overdose appears to be heightened with the coadministration of either benzodiazepines or sedative/hypnotics. To conclude, as with all interventions in medicine, buprenorphine treatment for narcotic addiction has a clinically fluctuating risk/benefit equation that must be continually monitored.
BT - Innovations in clinical neuroscience
C5 - Opioids & Substance Use
CP - 3-4
CY - United States
IS - 3-4
JF - Innovations in clinical neuroscience
N2 - While most clinicians will never prescribe buprenorphine or combined buprenorphine/naloxone, familiarity with the risks of these pharmacological approaches to the treatment of narcotic addiction remains relevant. Overall, medication-assisted treatment has clearly resulted in meaningful gains for a number of individuals who are addicted to narcotics (i.e., opiates and opioids). However, a certain level of risk is inherent with these approaches. For example, both buprenorphine and buprenorphine/naloxone may be diverted and misused (e.g., intravenously injected, intranasally administered), particularly buprenorphine. Likewise, when illicitly injected, both can cause infectious complications as well as result in death from overdose. The risk of death with buprenorphine overdose appears to be heightened with the coadministration of either benzodiazepines or sedative/hypnotics. To conclude, as with all interventions in medicine, buprenorphine treatment for narcotic addiction has a clinically fluctuating risk/benefit equation that must be continually monitored.
PP - United States
PY - 2015
SN - 2158-8333; 2158-8333
SP - 32
EP - 36
EP - 
T1 - Buprenorphine treatment for narcotic addiction: not without risks
T2 - Innovations in clinical neuroscience
TI - Buprenorphine treatment for narcotic addiction: not without risks
U1 - Opioids & Substance Use
U2 - 25973324
VL - 12
VO - 2158-8333; 2158-8333
Y1 - 2015
ER -